Soleus Capital Management, L.P.

Soleus Capital provides discretionary investment management to privately offered pooled funds and special purpose vehicles, including hedge funds, private equity vehicles, and credit strategies, and reported approximately $3.66 billion in assets under management as of December 31, 2025. Fees are charged at the fund level and generally consist of asset-based management fees and performance allocations as set forth in each Fund’s offering documents.

The firm pursues a fundamentals-driven strategy concentrated in the healthcare sector, using long/short equity approaches for its hedge funds and middle-to-late‑stage equity, convertible and debt instruments for its private equity and credit strategies. Idea generation and due diligence emphasize scientific literature, field research, quantitative screens and broker discussions, and the firm relies on third‑party administrators and soft‑dollar research arrangements for valuation and investment support.

Distinctive features disclosed in the Brochure include the use of third‑party placement agents and the possibility of side letters that can change fees, liquidity rights or information access for particular investors, together with documented policies to address the conflicts those arrangements create. The firm’s compliance policies also impose an unusual trading restriction on employees (limiting personal trading in the Health Care GICS sector), the Brochure was recently updated to address artificial intelligence and evolving regulatory risks, and the firm states it is not registered as a commodity pool operator or commodity trading advisor.